{
    "ticker": "ARGX",
    "name": "Argenx SE",
    "description": "Argenx SE is a biotechnology company focused on developing and delivering innovative therapies for patients with severe autoimmune diseases and cancer. Founded in 2008 and headquartered in Ghent, Belgium, Argenx leverages its proprietary immunology platform to discover and develop monoclonal antibodies that target the underlying mechanisms of disease. The company\u2019s lead product, efgartigimod, is an immunoglobulin G (IgG) modulating therapy that has shown promising results in treating various autoimmune conditions, including myasthenia gravis. Argenx aims to improve the lives of patients through the development of transformative treatments that address unmet medical needs. With a robust pipeline, the company is also exploring applications in oncology and other diseases where modulation of the immune system can provide therapeutic benefit. Argenx is committed to scientific excellence and collaboration, partnering with leading organizations to accelerate its research and development efforts. The company is listed on the NASDAQ under the ticker symbol ARGX, symbolizing its commitment to innovation and growth in the biotech sector.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Ghent, Belgium",
    "founded": "2008",
    "website": "https://www.argenx.com",
    "ceo": "Tim Van Hauwermeiren",
    "social_media": {
        "twitter": "https://twitter.com/argenx",
        "linkedin": "https://www.linkedin.com/company/argenx/"
    },
    "investor_relations": "https://investors.argenx.com",
    "key_executives": [
        {
            "name": "Tim Van Hauwermeiren",
            "position": "CEO"
        },
        {
            "name": "Kurt G. B. De Smet",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Efgartigimod"
            ]
        }
    ],
    "seo": {
        "meta_title": "Argenx SE | Innovative Therapies for Autoimmune Diseases and Cancer",
        "meta_description": "Explore Argenx SE, a leader in biotechnology focused on developing transformative therapies for severe autoimmune diseases and cancer. Learn about our innovative products and commitment to patient care.",
        "keywords": [
            "Argenx",
            "Biotechnology",
            "Autoimmune Diseases",
            "Cancer Therapies",
            "Efgartigimod"
        ]
    },
    "faq": [
        {
            "question": "What is Argenx known for?",
            "answer": "Argenx is known for developing innovative therapies for severe autoimmune diseases and cancer, particularly its lead product, efgartigimod."
        },
        {
            "question": "Who is the CEO of Argenx?",
            "answer": "Tim Van Hauwermeiren is the CEO of Argenx SE."
        },
        {
            "question": "Where is Argenx headquartered?",
            "answer": "Argenx is headquartered in Ghent, Belgium."
        },
        {
            "question": "What are Argenx's main products?",
            "answer": "Argenx's main product is efgartigimod, an IgG-modulating therapy for autoimmune conditions."
        },
        {
            "question": "When was Argenx founded?",
            "answer": "Argenx was founded in 2008."
        }
    ],
    "competitors": [
        "REGN",
        "AMGN",
        "GILD",
        "BMY"
    ],
    "related_stocks": [
        "NVAX",
        "SRPT",
        "ALNY",
        "EDIT"
    ]
}